Phase II study on Bortezomib (BTZ) in multiple relapsed or refractory pediatric acute lymphoblastic leukemia (rALL): high response rate with a modestly intensive regimen including BTZ, not related to pharmacokinetics

http://ift.tt/2umSYZG